JP2022554187A5 - - Google Patents

Info

Publication number
JP2022554187A5
JP2022554187A5 JP2022524084A JP2022524084A JP2022554187A5 JP 2022554187 A5 JP2022554187 A5 JP 2022554187A5 JP 2022524084 A JP2022524084 A JP 2022524084A JP 2022524084 A JP2022524084 A JP 2022524084A JP 2022554187 A5 JP2022554187 A5 JP 2022554187A5
Authority
JP
Japan
Prior art keywords
antigen
binding fragment
sequence
modified antibody
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022524084A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022554187A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/057209 external-priority patent/WO2021081440A2/en
Publication of JP2022554187A publication Critical patent/JP2022554187A/ja
Publication of JP2022554187A5 publication Critical patent/JP2022554187A5/ja
Priority to JP2025134949A priority Critical patent/JP2025169343A/ja
Pending legal-status Critical Current

Links

JP2022524084A 2019-10-24 2020-10-23 キメラサイトカイン改変抗体およびその使用方法 Pending JP2022554187A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025134949A JP2025169343A (ja) 2019-10-24 2025-08-14 キメラサイトカイン改変抗体およびその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962925740P 2019-10-24 2019-10-24
US62/925,740 2019-10-24
PCT/US2020/057209 WO2021081440A2 (en) 2019-10-24 2020-10-23 Chimeric cytokine modified antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025134949A Division JP2025169343A (ja) 2019-10-24 2025-08-14 キメラサイトカイン改変抗体およびその使用方法

Publications (2)

Publication Number Publication Date
JP2022554187A JP2022554187A (ja) 2022-12-28
JP2022554187A5 true JP2022554187A5 (cg-RX-API-DMAC7.html) 2023-10-31

Family

ID=73449235

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022524084A Pending JP2022554187A (ja) 2019-10-24 2020-10-23 キメラサイトカイン改変抗体およびその使用方法
JP2025134949A Pending JP2025169343A (ja) 2019-10-24 2025-08-14 キメラサイトカイン改変抗体およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025134949A Pending JP2025169343A (ja) 2019-10-24 2025-08-14 キメラサイトカイン改変抗体およびその使用方法

Country Status (7)

Country Link
US (1) US20220380487A1 (cg-RX-API-DMAC7.html)
EP (1) EP4048405A2 (cg-RX-API-DMAC7.html)
JP (2) JP2022554187A (cg-RX-API-DMAC7.html)
CN (1) CN115551594A (cg-RX-API-DMAC7.html)
AU (1) AU2020371784A1 (cg-RX-API-DMAC7.html)
CA (1) CA3158893A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021081440A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
US20250197525A1 (en) * 2021-04-28 2025-06-19 Minotaur Therapeutics, Inc. Humanized chimeric bovine antibodies and methods of use

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3887699A (en) 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3486459D1 (de) 1983-09-26 1997-12-11 Udo Dr Med Ehrenfeld Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
DE3413608A1 (de) 1984-04-11 1985-10-24 Hoechst Ag, 6230 Frankfurt Implantierbare zubereitungen von regulatorischen peptiden mit gesteuerter freisetzung und verfahren zu ihrer herstellung
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
IT1247472B (it) 1991-05-31 1994-12-17 Fidia Spa Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
JPH08503950A (ja) 1992-12-02 1996-04-30 アルカーメス・コントロールド・セラピユーテイクス・インコーポレーテツド 徐放性成長ホルモン含有マイクロスフェア
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
EP1002529A1 (en) 1994-09-09 2000-05-24 Takeda Chemical Industries, Ltd. Sustained-release preparation containing a metal salt of a peptide
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
ES2170853T3 (es) 1995-03-28 2002-08-16 Fidia Advanced Biopolymers Srl Nanosferas que comprenden un polisacarido biocompatible.
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
SK281571B6 (sk) 1995-06-07 2001-05-10 Alkermes Controlled Therapeutics, Inc. Prostriedok na trvalé uvoľňovanie ľudského rastového hormónu
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
AU2660397A (en) 1996-04-05 1997-10-29 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
US6083715A (en) 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6566329B1 (en) 1999-06-28 2003-05-20 Novo Nordisk A/S Freeze-dried preparation of human growth hormone
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
EP1531757B1 (en) 2002-07-19 2016-09-07 Omeros Corporation Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
EP1576952A1 (en) 2004-03-18 2005-09-21 OctoPlus Technologies B.V. Hydrogel microspheres with improved release profile
EP1777294A1 (en) * 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
JP4616237B2 (ja) 2006-11-07 2011-01-19 日本電信電話株式会社 シリコン化合物薄膜の形成方法
EP2537933A1 (en) * 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
EP2802601B1 (en) * 2012-01-09 2019-11-13 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
US20140050720A1 (en) * 2012-01-09 2014-02-20 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
JP6687520B2 (ja) * 2013-07-18 2020-04-22 トーラス バイオサイエンシズ リミテッド ライアビリティ カンパニー 極めて長い相補性決定領域を有するヒト化抗体
KR102461885B1 (ko) * 2017-04-03 2022-11-03 에프. 호프만-라 로슈 아게 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체

Similar Documents

Publication Publication Date Title
US20220340676A1 (en) Modified human igm constant regions for modulation of complement-dependent cytolysis effector function
JP7282383B2 (ja) タンパク質性ヘテロ二量体及びその用途
TWI838621B (zh) 具有經修飾重鏈恆定區之多特異性重鏈抗體
ES2874558T3 (es) Moléculas de unión a CD20 y usos de las mismas
US20230203119A1 (en) Immunostimulatory multimeric binding molecules
JP2018526974A (ja) Pdl−1抗体、その医薬組成物及びその使用
JP2022545655A (ja) 多量体の二重特異性抗cd123結合分子及びその使用
KR20230005228A (ko) Pd-1 효능제 다량체 결합 분자
KR20220050166A (ko) Igm 글리코변이체
JP2024507693A5 (cg-RX-API-DMAC7.html)
KR20230146022A (ko) 항-cd123 결합 분자 및 이의 용도
US20250051473A1 (en) Anti-cd38 binding molecules and uses thereof
WO2023064900A1 (en) Methods of use of multimeric anti-pd-l1 binding molecules
CA3213875A1 (en) Novel tnfr2 binding molecules
WO2023178253A2 (en) Use of a multimeric anti-pd-l1 binding molecule in combination with a monoclonal antibody therapy
WO2019154420A1 (zh) Il17抗体及其应用
US20250011431A1 (en) Anti-canine pd-l1 antibodies
TW202544034A (zh) 結合至cd28及nectin-4之雙特異性抗體
KR20250069526A (ko) 이중특이적 폴리펩타이드 및 이의 용도
CN118679185A (zh) 抗cd38结合分子及其用途
RU2020117441A (ru) Биспецифические 2+1 конторстела
HK1241931B (en) Cd20 binding molecules and uses thereof